 |
Sangamo BioSciences Announces Presentation at 2012 Leerink Swann Global Healthcare Conference
Feb 9, 2012
|
7.5 KB |
|
| |
RICHMOND, Calif., Feb. 9, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 2:30 pm ET on Thursday, February 16, 2012, at ...
|
|
Sangamo BioSciences Reports Fourth Quarter and Full Year 2011 Financial Results
Feb 8, 2012
|
18.4 KB |
|
| |
RICHMOND, Calif., Feb. 8, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported fourth quarter and full year 2011 financial results and accomplishments.
For the fourth quarter ended December 31, 2011, Sangamo reported a consolidated net loss of $6.4 million, or $0.12 per share, compared to a net loss of $8.3 million, or ...
|
|
Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
Feb 1, 2012
|
7.9 KB |
|
| |
RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2011 financial results on Wednesday, February 8, 2012, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the publ...
|
|
Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases
Feb 1, 2012
|
12.8 KB |
|
| |
DUBLIN and RICHMOND, Calif., Feb. 1, 2012 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, and Sangamo BioSciences, Inc. (NASDAQ: SGMO), a leader in genome-editing technology, announced today that they have entered into a collaboration and license agreement to develop therapeutics for hemophilia a...
|
|
Sangamo BioSciences Announces Initiation of Two New Phase 2 HIV Clinical Trials
Jan 9, 2012
|
16.9 KB |
|
| |
RICHMOND, Calif., Jan. 9, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the initiation of two new Phase 2 clinical studies (SB-728-1101 and SB-728-902, Cohort 5) in its program to develop a "functional cure" for HIV/AIDS. Sangamo's ZFP Therapeutic® approach (SB-728-T) generates T-cells that are resistant to HIV ...
|
|
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
Jan 5, 2012
|
7.5 KB |
|
| |
RICHMOND, Calif., Jan. 5, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 7:30 am PT (10:30 am ET) on Thursday, January ...
|
|
Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Dec 13, 2011
|
11.5 KB |
|
| |
RICHMOND, Calif., Dec. 13, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new data demonstrating the ability to permanently correct a disease gene in an adult mouse model of hemophilia B using systemic delivery of zinc finger nucleases (ZFNs) at the 53nd Annual Meeting of the American Society of Hematolo...
|
|
Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
Nov 8, 2011
|
7.5 KB |
|
| |
RICHMOND, Calif., Nov. 8, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 11:00 am ET on Tuesday, November 15, 2011 at t...
|
|
Sangamo BioSciences Reports Third Quarter 2011 Financial Results
Oct 25, 2011
|
16.6 KB |
|
| |
RICHMOND, Calif., Oct. 25, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today reported third quarter 2011 financial results and accomplishments.
For the third quarter ended September 30, 2011, Sangamo reported a consolidated net loss of $9.6 million, or $0.18 per share, compared to a net loss of $8.7 million, or $0.19 per share...
|
|
Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Oct 18, 2011
|
8.0 KB |
|
| |
RICHMOND, Calif., Oct. 18, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its third quarter 2011 financial results on Tuesday, October 25, 2011, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone...
|
|
Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
Oct 14, 2011
|
7.5 KB |
|
| |
RICHMOND, Calif., Oct. 14, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 9:30 am ET on Friday, October 21, 2011 at the...
|
|
Sangamo BioSciences Announces Publication in Nature of Gene Correction Strategy for Alpha 1-Antitrypsin Deficiency
Oct 13, 2011
|
11.0 KB |
|
| |
RICHMOND, Calif., Oct. 13, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of a preclinical study demonstrating highly specific, functional correction of the alpha 1-antitrypsin (A1AT) gene defect in patient-derived induced pluripotent stem cells (iPSCs) using zinc finger nucleases (ZFNs). The study, publish...
|
|
Sangamo BioSciences Announces Phase 2b Trial of SB-509 in Diabetic Neuropathy Did Not Meet Key Study Endpoints
Oct 3, 2011
|
13.5 KB |
|
| |
RICHMOND, Calif., Oct. 3, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that its Phase 2b study (SB-509-901) did not meet its primary or secondary clinical endpoints in subjects with moderate severity diabetic neuropathy (DN) as compared to placebo.
"We are disappointed that this trial did not produce a better ou...
|
|
Sangamo BioSciences to Host Conference Call to Discuss Results From Phase 2b Trial of SB-509 in Diabetic Neuropathy
Sep 30, 2011
|
8.2 KB |
|
| |
RICHMOND, Calif., Sept. 30, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will hold a teleconference and webcast at 8:30 am ET, on Monday, October 3, 2011, to discuss results of the Phase 2b clinical trial (SB-509-901) from its ZFP Therapeutic® program to develop SB-509 as a treatment for diabet...
|
|
Sangamo BioSciences Announces Presentation at the Sixth Annual JMP Securities Healthcare Conference
Sep 21, 2011
|
7.6 KB |
|
| |
RICHMOND, Calif., Sept. 21, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3:30 pm ET on Tuesday, September 27, 2011 at...
|
|
Sangamo BioSciences Announces Presentation of Groundbreaking Clinical Data From ZFN Therapeutic for HIV/AIDS at ICAAC 2011
Sep 18, 2011
|
17.4 KB |
|
| |
RICHMOND, Calif., Sept. 18, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach for the treatment of HIV/AIDS, were discussed in two presentations at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). T...
|
|
Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
Sep 14, 2011
|
7.9 KB |
|
| |
RICHMOND, Calif., Sept. 14, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an overview of the company's business strategy at 7:30 am ET on Wednesday, September 21, 2011 at the UBS 2011 Global Life Sciences Conference which will be held in New York City.
...
|
|
Sangamo BioSciences Announces New SB-728-T HIV/AIDS Data to be Presented at 51st ICAAC
Sep 8, 2011
|
9.3 KB |
|
| |
RICHMOND, Calif., Sept. 8, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that data from all dosing cohorts of its Phase 1 study (SB-728-902) to evaluate SB-728-T for HIV/AIDS as well as preliminary data from the Phase 1 clinical study of the same drug, ongoing at the University of Pennsylvania, will be presented at t...
|
|
Sangamo BioSciences Announces Presentation at the Stifel Nicolaus 2011 Healthcare Conference
Sep 1, 2011
|
7.6 KB |
|
| |
RICHMOND, Calif., Sept. 1, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3:50 pm ET on Thursday, September 8, 2011 at ...
|
|
Sangamo BioSciences Announces Presentation at the Wedbush Securities 2011 Life Sciences Management Access Conference
Aug 10, 2011
|
7.7 KB |
|
| |
RICHMOND, Calif., Aug. 10, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 11:10 am ET on Wednesday, August 17, 2011 at ...
|
|
|
delicious
Digg
Facebook
LinkedIn
Twitter
Yahoo! Buzz
